Cerebrospinal Fluid Biomarkers in Neurodegenerative Disorders

References

• Burchell JT, Panegyres PK. Novel CSF biomarkers for Alzheimer's disease. Future Neurol. 10(6), 511–514 (2015).
   Google Scholar
• Ritchie C, Smailagic N, Noel-Storr AH, Ukoumunne O, Ladds EC, Martin S. CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst. Rev. 3, CD010803 (2017).
   PubMedGoogle Scholar
• Parnetti L, Eusebi P. Cerebrospinal fluid biomarkers in Alzheimer's disease: an invaluable tool for clinical diagnosis and trial enrichment. J. Alzheimer's Dis. 64(s1), S281–S287 (2018).
   PubMedGoogle Scholar
• Wang HF, Tan L, Cao L et al. Application of the IWG-2 diagnostic criteria for Alzheimer's disease to the ADNI. J. Alzheimer's Dis. 51(1), 227–236 (2016).
   PubMed Web of Science ®Google Scholar
• Blanco-Cantó ME, Monge-Argilés JA, Pérez-Cejuela C et al. Diagnostic validity comparison between criteria based on CSF Alzheimer's disease biomarkers. Am. J. Alzheimer's Dis. Other Demen. 32(2), 101–107 (2017).
   PubMed Web of Science ®Google Scholar
• Janelidze S, Zetterberg H, Mattsson N et al. CSF Abeta42/Abeta40 and Abeta42/Abeta38 ratios: better diagnostic markers of Alzheimer disease. Ann. Clin. Transl. Neurol. 3(3), 154–165 (2016).
   PubMed Web of Science ®Google Scholar
• Leuzy ACK, Pannee J, Hasselbalch S et al. Improved concordance between [11C]PIB PET and CSF AB42 using AB42/AB40: findings from a multicenter European memory clinic population. Neurobiol. Aging 39(Suppl. 1), S18 (2016).
   Google Scholar
• Gabelle A, Roche S, Geny C et al. Correlations between soluble alpha/beta forms of amyloid precursor protein and Abeta38, 40, and 42 in human cerebrospinal fluid. Brain Res. 1357 175–183 (2010).
   PubMed Web of Science ®Google Scholar
• Koychev I, Galna B, Zetterberg H et al. Abeta42/Abeta40 and Abeta42/Abeta38 ratios are associated with measures of gait variability and activities of daily living in mild Alzheimer's disease: a pilot study. J. Alzheimer's Dis. 65(4), 1377–1383 (2018).
   PubMed Web of Science ®Google Scholar
• Olsson B, Lautner R, Andreasson U et al. CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. Lancet Neurol. 15(7), 673–684 (2016).
   PubMed Web of Science ®Google Scholar
• Ohrfelt A, Johansson P, Wallin A et al. Increased cerebrospinal fluid levels of ubiquitin carboxyl-terminal hydrolase L1 in patients with Alzheimer's disease. Dement. Geriatr. Cogn. Dis. Extra 6(2), 283–294 (2016).
   PubMedGoogle Scholar
• Wang H, Wang T, Qian S, Ba L, Lin Z, Xiao S. A pilot longitudinal study on cerebrospinal fluid (CSF) tau protein in Alzheimer's disease and vascular dementia. Shanghai Arch. Psychiatry 28(5), 271–279 (2016).
   PubMedGoogle Scholar
• Kidemet-Piskac S, Babic Leko M, Blazekovic A et al. Evaluation of cerebrospinal fluid phosphorylated tau231 as a biomarker in the differential diagnosis of Alzheimer's disease and vascular dementia. CNS Neurosci. Ther. 24(8), 734–740 (2018).
   PubMed Web of Science ®Google Scholar
• Pouclet-Courtemanche HNT, Schraen S, Pasquier F, Dumurgier J, Paquet C, Lebouvier T. Clinical profile of patients with normal CSF ab42 and Ab42/Ab40 ratio, yet abnormal CSF 181p-tau: a snap story. Alzheimer's Dementia 13(7), P343 (2017).
   Google Scholar
• Mattsson N, Smith R, Strandberg O et al. Comparing (18)F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer's disease. Neurology 90(5), e388–e395 (2018).
   PubMed Web of Science ®Google Scholar
• Antonell A, Mansilla A, Rami L et al. Cerebrospinal fluid level of YKL-40 protein in preclinical and prodromal Alzheimer's disease. J. Alzheimer's Dis. 42(3), 901–908 (2014).
   PubMed Web of Science ®Google Scholar
• Galasko DR, Shaw LM. CSF biomarkers for Alzheimer disease – approaching consensus. Nat. Rev. Neurol. 13, 131 (2017).
   PubMed Web of Science ®Google Scholar
• Faull M, Ching SY, Jarmolowicz AI, Beilby J, Panegyres PK. Comparison of two methods for the analysis of CSF Abeta and tau in the diagnosis of Alzheimer's disease. Am. J. Neurodegener. Dis. 3(3), 143–151 (2014).
   PubMedGoogle Scholar
• Bonneh-Barkay D, Bissel SJ, Wang G et al. YKL-40, a marker of simian immunodeficiency virus encephalitis, modulates the biological activity of basic fibroblast growth factor. Am. J. Pathol. 173(1), 130–143 (2008).
   PubMed Web of Science ®Google Scholar
• Kirkwood CM, Macdonald ML, Schempf TA et al. Altered levels of Visinin-Like Protein 1 correspond to regional neuronal loss in Alzheimer's disease and frontotemporal lobar degeneration. J. Neuropathol. Exp. Neurol. 75(2), 175–182 (2016).
   PubMed Web of Science ®Google Scholar
• Gaiottino J, Norgren N, Dobson R et al. Increased neurofilament light chain blood levels in neurodegenerative neurological diseases. PLoS ONE 8(9), e75091 (2013).
   PubMed Web of Science ®Google Scholar
• Muszynski P, Kulczynska-Przybik A, Borawska R et al. The relationship between markers of inflammation and degeneration in the central nervous system and the blood-brain barrier impairment in Alzheimer's disease. J. Alzheimer's Dis. 59(3), 903–912 (2017).
   PubMed Web of Science ®Google Scholar
• Kester MI, Teunissen CE, Sutphen C et al. Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer's disease in a memory clinic cohort. Alzheimer's Res. Ther. 7(1), 59 (2015).
   PubMed Web of Science ®Google Scholar
• Oeckl P, Steinacker P, Feneberg E, Otto M. Neurochemical biomarkers in the diagnosis of frontotemporal lobar degeneration: an update. J. Neurochem. 138(Suppl 1), 184–192 (2016).
   PubMedGoogle Scholar
• Li D, Shen D, Tai H, Cui L. Neurofilaments in CSF as diagnostic biomarkers in motor neuron disease: a meta-analysis. Front. Aging Neurosci. 8, 290 (2016).
   PubMed Web of Science ®Google Scholar
• Mattsson N, Insel PS, Palmqvist S et al. Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease. EMBO Mol. Med. 8(10), 1184–1196 (2016).
   PubMed Web of Science ®Google Scholar
• Abu-Rumeileh S, Capellari S, Stanzani-Maserati M et al. The CSF neurofilament light signature in rapidly progressive neurodegenerative dementias. Alzheimer's Res. Ther. 10(1), 3 (2018).
   PubMedGoogle Scholar
• Blennow K. A review of fluid biomarkers for alzheimer's disease: moving from CSF to blood. Neurol. Ther. 6(Suppl 1), 15–24 (2017).
   PubMed Web of Science ®Google Scholar
• Wellington H, Paterson RW, Portelius E et al. Increased CSF neurogranin concentration is specific to Alzheimer disease. Neurology 86(9), 829–835 (2016).
   PubMed Web of Science ®Google Scholar
• Kvartsberg H, Duits FH, Ingelsson M et al. Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease. Alzheimer's Dement. 11(10), 1180–1190 (2015).
   PubMed Web of Science ®Google Scholar
• Wellington H, Paterson RW, Suarez-Gonzalez A et al. CSF neurogranin or tau distinguish typical and atypical Alzheimer disease. Ann. Clin. Transl. Neurol. 5(2), 162–171 (2018).
   PubMed Web of Science ®Google Scholar
• Portelius E, Olsson B, Hoglund K et al. Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology. Acta Neuropathol. 136(3), 363–376 (2018).
   PubMed Web of Science ®Google Scholar
• Wang Q, Woltjer RL, Cimino PJ et al. Proteomic analysis of neurofibrillary tangles in Alzheimer disease identifies GAPDH as a detergent-insoluble paired helical filament tau binding protein. FASEB J. 19(7), 869–871 (2005).
   PubMedGoogle Scholar
• Haque A, Polcyn R, Matzelle D, Banik NL. New insights into the role of neuron-specific enolase in neuro-inflammation, neurodegeneration and neuroprotection. Brain Sci. 8(2), 33 (2018).
   PubMed Web of Science ®Google Scholar
• Schmidt FM, Mergl R, Stach B, Jahn I, Gertz HJ, Schonknecht P. Elevated levels of cerebrospinal fluid neuron-specific enolase (NSE) in Alzheimer's disease. Neurosci. Lett. 570, 81–85 (2014).
   PubMed Web of Science ®Google Scholar
• Meeter LHH, Vijverberg EG, Del Campo M et al. Clinical value of neurofilament and phospho-tau/tau ratio in the frontotemporal dementia spectrum. Neurology 90(14), e1231–e1239 (2018).
   PubMed Web of Science ®Google Scholar
• Hu WT, Watts K, Grossman M et al. Reduced CSF p-Tau181 to Tau ratio is a biomarker for FTLD-TDP. Neurology 81(22), 1945–1952 (2013).
   PubMed Web of Science ®Google Scholar
• Borroni B, Benussi A, Archetti S et al. Csf p-tau181/tau ratio as biomarker for TDP pathology in frontotemporal dementia. Amyotroph. Lateral Scler. Front. Degener. 16(1-2), 86–91 (2015).
   PubMed Web of Science ®Google Scholar
• Vergallo A, Carlesi C, Pagni C et al. A single center study: Abeta42/p-Tau181 CSF ratio to discriminate AD from FTD in clinical setting. Neurol. Sci. 38(10), 1791–1797 (2017).
   PubMed Web of Science ®Google Scholar
• Alcolea D, Vilaplana E, Suarez-Calvet M et al. CSF sAPPbeta, YKL-40, and neurofilament light in frontotemporal lobar degeneration. Neurology 89(2), 178–188 (2017).
   PubMed Web of Science ®Google Scholar
• Teunissen CE, Elias N, Koel-Simmelink MJ et al. Novel diagnostic cerebrospinal fluid biomarkers for pathologic subtypes of frontotemporal dementia identified by proteomics. Alzheimer's Dement. 2, 86–94 (2016).
   Google Scholar
• Baldacci F, Toschi N, Lista S et al. Two-level diagnostic classification using cerebrospinal fluid YKL-40 in Alzheimer's disease. Alzheimer's Dement. 13(9), 993–1003 (2017).
   PubMed Web of Science ®Google Scholar
• Scherling CS, Hall T, Berisha F et al. Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration. Ann. Neurol. 75(1), 116–126 (2014).
   PubMed Web of Science ®Google Scholar
• Skillback T, Mattsson N, Blennow K, Zetterberg H. Cerebrospinal fluid neurofilament light concentration in motor neuron disease and frontotemporal dementia predicts survival. Amyotroph. Lateral Scler. Front. Degener. 18(5-6), 397–403 (2017).
   PubMed Web of Science ®Google Scholar
• Aguzzi A, Zhu C. Microglia in prion diseases. J. Clin. Investig. 127(9), 3230–3239 (2017).
   PubMed Web of Science ®Google Scholar
• Aguzzi A, Nuvolone M, Zhu C. The immunobiology of prion diseases. Nat. Rev. Immunol. 13(12), 888–902 (2013).
   PubMed Web of Science ®Google Scholar
• Atarashi R, Sano K, Satoh K, Nishida N. Real-time quaking-induced conversion: a highly sensitive assay for prion detection. Prion 5(3), 150–153 (2011).
   PubMed Web of Science ®Google Scholar
• Kang HE, Mo Y, Abd Rahim R, Lee HM, Ryou C. Prion diagnosis: application of real-time quaking-induced conversion. Biomed. Res. Int. 2017(1), 1–8 (2017).
   Google Scholar
• Satoh K, Atarashi R, Nishida N. Real-time quaking-induced conversion for diagnosis of prion disease. Methods Mol. Biol. 1658, 305–310 (2017).
   PubMedGoogle Scholar
• Matsui Y, Satoh K, Miyazaki T et al. High sensitivity of an ELISA kit for detection of the gamma-isoform of 14–3-3 proteins: usefulness in laboratory diagnosis of human prion disease. BMC Neurol. 11, 120 (2011).
   PubMed Web of Science ®Google Scholar
• Lattanzio F, Abu-Rumeileh S, Franceschini A et al. Prion-specific and surrogate CSF biomarkers in Creutzfeldt-Jakob disease: diagnostic accuracy in relation to molecular subtypes and analysis of neuropathological correlates of p-tau and Abeta42 levels. Acta Neuropathol. 133(4), 559–578 (2017).
   PubMed Web of Science ®Google Scholar
• Abu Rumeileh S, Lattanzio F, Stanzani Maserati M, Rizzi R, Capellari S, Parchi P. Diagnostic accuracy of a combined analysis of cerebrospinal fluid t-PrP, t-tau, p-tau, and Abeta42 in the differential diagnosis of Creutzfeldt-Jakob disease from Alzheimer's disease with emphasis on atypical disease variants. J. Alzheimer's Dis. 55(4), 1471–1480 (2017).
   PubMed Web of Science ®Google Scholar
• Zerr I, Schmitz M, Karch A et al. Cerebrospinal fluid neurofilament light levels in neurodegenerative dementia: evaluation of diagnostic accuracy in the differential diagnosis of prion diseases. Alzheimer's Dement. 14(6), 751–763 (2018).
   PubMed Web of Science ®Google Scholar
• Oberstadt M, Classen J, Arendt T, Holzer M. TDP-43 and cytoskeletal proteins in ALS. Mol. Neurobiol. 55(4), 3143–3151 (2018).
   PubMed Web of Science ®Google Scholar
• Weydt P, Oeckl P, Huss A et al. Neurofilament levels as biomarkers in asymptomatic and symptomatic familial amyotrophic lateral sclerosis. Ann. Neurol. 79(1), 152–158 (2016).
   PubMed Web of Science ®Google Scholar
• Li S, Ren Y, Zhu W, Yang F, Zhang X, Huang X. Phosphorylated neurofilament heavy chain levels in paired plasma and CSF of amyotrophic lateral sclerosis. J. Neurol. Sci. 367, 269–274 (2016).
   PubMed Web of Science ®Google Scholar
• Blasco H, Veyrat-Durebex C, Bocca C et al. Lipidomics reveals cerebrospinal-fluid signatures of ALS. Sci. Rep. 7(1), 17652 (2017).
   PubMedGoogle Scholar
• Drannik A, Martin J, Peterson R, Ma X, Jiang F, Turnbull J. Cerebrospinal fluid from patients with amyotrophic lateral sclerosis inhibits Sonic Hedgehog function. PLoS ONE 12(2), e0171668 (2017).
   PubMed Web of Science ®Google Scholar
• Andersen AD, Binzer M, Stenager E, Gramsbergen JB. Cerebrospinal fluid biomarkers for Parkinson's disease – a systematic review. Acta Neurol. Scand. 135(1), 34–56 (2017).
   PubMed Web of Science ®Google Scholar
• Jimenez-Jimenez FJ, Alonso-Navarro H, Garcia-Martin E, Agundez JA. Cerebrospinal fluid biochemical studies in patients with Parkinson's disease: toward a potential search for biomarkers for this disease. Front. Cell Neurosci. 8, 369 (2014).
   PubMed Web of Science ®Google Scholar
• Hong Z, Shi M, Chung KA et al. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 133(Pt 3), 713–726 (2010).
   PubMed Web of Science ®Google Scholar
• Herbert MK, Eeftens JM, Aerts MB et al. CSF levels of DJ-1 and tau distinguish MSA patients from PD patients and controls. Parkinsonism Relat. Disord. 20(1), 112–115 (2014).
   PubMed Web of Science ®Google Scholar
• Sjodin S, Hansson O, Ohrfelt A et al. Mass spectrometric analysis of cerebrospinal fluid ubiquitin in Alzheimer's disease and Parkinsonian disorders. Proteom. Clin. Appl. 11(11–12), (2017).
   PubMed Web of Science ®Google Scholar
• Magdalinou N, Lees AJ, Zetterberg H. Cerebrospinal fluid biomarkers in parkinsonian conditions: an update and future directions. J. Neurol. Neurosurg. Psychiatry 85(10), 1065–1075 (2014).
   PubMed Web of Science ®Google Scholar
• Magdalinou NK, Paterson RW, Schott JM et al. A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes. J. Neurol. Neurosurg. Psychiatry 86(11), 1240–1247 (2015).
   PubMed Web of Science ®Google Scholar
• Constantinides VC, Paraskevas GP, Emmanouilidou E et al. CSF biomarkers beta-amyloid, tau proteins and a-synuclein in the differential diagnosis of Parkinson-plus syndromes. J. Neurol. Sci. 382, 91–95 (2017).
   PubMed Web of Science ®Google Scholar
• Kumar S, Reddy PH. Are circulating microRNAs peripheral biomarkers for Alzheimer's disease? Biochim. Biophys. Acta 1862(9), 1617–1627 (2016).
   PubMed Web of Science ®Google Scholar